| Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer H Borghaei, L Paz-Ares, L Horn, DR Spigel, M Steins, NE Ready, ... New England Journal of Medicine 373 (17), 1627-1639, 2015 | 9917 | 2015 |
| Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer NA Rizvi, MD Hellmann, A Snyder, P Kvistborg, V Makarov, JJ Havel, ... Science 348 (6230), 124-128, 2015 | 8255 | 2015 |
| Pembrolizumab for the treatment of non–small-cell lung cancer EB Garon, NA Rizvi, R Hui, N Leighl, AS Balmanoukian, JP Eder, ... New England Journal of Medicine 372 (21), 2018-2028, 2015 | 6597 | 2015 |
| Nivolumab plus ipilimumab in advanced melanoma JD Wolchok, H Kluger, MK Callahan, MA Postow, NA Rizvi, AM Lesokhin, ... New England Journal of Medicine 369 (2), 122-133, 2013 | 5093 | 2013 |
| Tumor mutational load predicts survival after immunotherapy across multiple cancer types RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ... Nature genetics 51 (2), 202-206, 2019 | 3295 | 2019 |
| Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade N McGranahan, AJS Furness, R Rosenthal, S Ramskov, R Lyngaa, ... Science 351 (6280), 1463-1469, 2016 | 3065 | 2016 |
| Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase … NA Rizvi, J Mazières, D Planchard, TE Stinchcombe, GK Dy, SJ Antonia, ... The lancet oncology 16 (3), 257-265, 2015 | 1689 | 2015 |
| Overall survival and long-term safety of nivolumab (anti–programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non–small-cell lung cancer SN Gettinger, L Horn, L Gandhi, DR Spigel, SJ Antonia, NA Rizvi, ... Journal of clinical oncology 33 (18), 2004-2012, 2015 | 1314 | 2015 |
| Association of pembrolizumab with tumor response and survival among patients with advanced melanoma A Ribas, O Hamid, A Daud, FS Hodi, JD Wolchok, R Kefford, AM Joshua, ... Jama 315 (15), 1600-1609, 2016 | 1138 | 2016 |
| Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study EB Garon, MD Hellmann, NA Rizvi, E Carcereny, NB Leighl, MJ Ahn, ... Journal of Clinical Oncology 37 (28), 2518-2527, 2019 | 1086 | 2019 |
| Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy D Chowell, LGT Morris, CM Grigg, JK Weber, RM Samstein, V Makarov, ... Science 359 (6375), 582-587, 2018 | 1039 | 2018 |
| Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study MD Hellmann, NA Rizvi, JW Goldman, SN Gettinger, H Borghaei, ... The lancet oncology 18 (1), 31-41, 2017 | 1028 | 2017 |
| Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non–small-cell lung cancer VA Miller, MG Kris, N Shah, J Patel, C Azzoli, J Gomez, LM Krug, W Pao, ... Journal of Clinical Oncology 22 (6), 1103-1109, 2004 | 953 | 2004 |
| Nivolumab versus docetaxel in previously treated patients with advanced non–small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials … L Horn, DR Spigel, EE Vokes, E Holgado, N Ready, M Steins, ... Journal of clinical oncology 35 (35), 3924-3933, 2017 | 892 | 2017 |
| Clinical course of patients with non–small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib GJ Riely, W Pao, DK Pham, AR Li, N Rizvi, ES Venkatraman, ... Clinical cancer research 12 (3), 839-844, 2006 | 864 | 2006 |
| Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer MD Hellmann, MK Callahan, MM Awad, E Calvo, PA Ascierto, A Atmaca, ... Cancer cell 33 (5), 853-861. e4, 2018 | 846 | 2018 |
| Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study S Antonia, SB Goldberg, A Balmanoukian, JE Chaft, RE Sanborn, A Gupta, ... The lancet oncology 17 (3), 299-308, 2016 | 664 | 2016 |
| Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised … A Sezer, S Kilickap, M Gümüş, I Bondarenko, M Özgüroğlu, M Gogishvili, ... The Lancet 397 (10274), 592-604, 2021 | 636 | 2021 |
| A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy M Łuksza, N Riaz, V Makarov, VP Balachandran, MD Hellmann, ... Nature 551 (7681), 517-520, 2017 | 620 | 2017 |
| Classification of current anticancer immunotherapies L Galluzzi, E Vacchelli, JM Bravo-San Pedro, A Buqué, L Senovilla, ... Oncotarget 5 (24), 12472, 2014 | 569 | 2014 |
